Efficacy of Glycopyrronium added to Budesonide/Formoterol in patients with Asthma-COPD overlap syndrome

Efficacy of Glycopyrronium added to Budesonide/Formoterol in patients with Asthma-COPD overlap syndrome - Efficacy of triple therapy in patients with Asthma-COPD overlap syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026651

Enrollment

Registered

2017-04-01

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with Asthma-COPD overlap syndrom

Interventions

Patients with ACOS treated by Budesonide/Formoterol 640 micro g/18micri g/day. Glycopyrronium 50 micro g/day is administered 4 weeks in patients with ACOS treated by Budesonide/Formoterol 640 micro

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with stable asthma COPD overlap syndrome

Exclusion criteria

Exclusion criteria: Patients with unstable asthma COPD overlap syndrome

Design outcomes

Primary

Measure	Time frame
Improvement of respiratory functions (FEV1, FVC) after 4 week treatment	—

Secondary

Measure	Time frame
Improvement of respiratory symptoms after 4 week treatment	—

Countries

Japan

Contacts

Public ContactYoshihisa Ishiura

Toyama City Hospital Respiratory Medicine

ishiura@tch.toyama.toyama.jp076-422-1112

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026